MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.88
+0.19
+2.84%
Closed 16:00 04/02 EDT
OPEN
6.75
PREV CLOSE
6.69
HIGH
6.94
LOW
6.11
VOLUME
114.93K
TURNOVER
--
52 WEEK HIGH
8.45
52 WEEK LOW
2.150
MARKET CAP
117.51M
P/E (TTM)
-2.1045
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NBSE stock price target is 15.60 with a high estimate of 18.00 and a low estimate of 13.00.

EPS

NBSE News

More
  • Oppenheimer Maintains Outperform on NeuBase Therapeutics, Raises Price Target to $17
  • Benzinga · 1d ago
  • Chardan Capital Maintains Buy on NeuBase Therapeutics, Raises Price Target to $18
  • Benzinga · 1d ago
  • NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL Platform
  • GlobeNewswire · 3d ago
  • NeuBase Therapeutics EPS beats by $0.06
  • seekingalpha · 03/27 01:16

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About NBSE

NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
More

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.